Pharnext SA
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of bac… Read more
Pharnext SA (PNEXF) - Net Assets
Latest net assets as of December 2023: $-33.95 Million USD
Based on the latest financial reports, Pharnext SA (PNEXF) has net assets worth $-33.95 Million USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.17 Million) and total liabilities ($38.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-33.95 Million |
| % of Total Assets | -813.89% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Pharnext SA - Net Assets Trend (2015–2023)
This chart illustrates how Pharnext SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pharnext SA (2015–2023)
The table below shows the annual net assets of Pharnext SA from 2015 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-33.95 Million | +1.26% |
| 2022-12-31 | $-34.38 Million | -92.56% |
| 2021-12-31 | $-17.86 Million | -42.64% |
| 2020-12-31 | $-12.52 Million | -72.77% |
| 2019-12-31 | $-7.25 Million | +72.50% |
| 2018-12-31 | $-26.35 Million | -119.75% |
| 2017-12-31 | $-11.99 Million | -415.47% |
| 2016-12-31 | $3.80 Million | +116.04% |
| 2015-12-31 | $-23.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharnext SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1815871100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $6.06 Million | % |
| Total Equity | $-33.95 Million | 100.00% |
Pharnext SA Competitors by Market Cap
The table below lists competitors of Pharnext SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vatic Ventures Corp.
PINK:VCVVF
|
$413.51K |
|
NISOURCE (NOU.SG)
STU:NOU
|
$413.58K |
|
Nykredit Invest Balance Mod KL
CO:NBIMOKL
|
$413.77K |
|
NexOptic Technology Corp
PINK:NXOPF
|
$413.79K |
|
FIRSTENERGY - Dusseldorf Stock Exchang
DU:FE7
|
$413.19K |
|
Ralliant Corporation Common Stock
NYSE:RAL
|
$412.83K |
|
AUBAY (BAQ.SG)
STU:BAQ
|
$412.05K |
|
Search Minerals Inc
PINK:SHCMF
|
$412.04K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharnext SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -34,384,540 to -33,951,475, a change of 433,065.
- Net loss of 27,517,420 reduced equity.
- Other factors increased equity by 27,950,485.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-27.52 Million | -81.05% |
| Other Changes | $27.95 Million | +82.32% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Pharnext SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1.07 | $1.00 | x |
| 2018-12-31 | $-2.18 | $1.00 | x |
| 2019-12-31 | $-0.48 | $1.00 | x |
| 2020-12-31 | $-0.65 | $1.00 | x |
| 2021-12-31 | $-0.14 | $1.00 | x |
| 2022-12-31 | $0.00 | $1.00 | x |
| 2023-12-31 | $-189.71 | $1.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharnext SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -275174.20%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-51.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | -417.82% | 0.42x | 0.00x | $-8.62 Million |
| 2016 | -459.09% | 0.00% | 0.00x | 5.98x | $-17.83 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.05 Million |
| 2018 | 0.00% | -793.39% | 0.09x | 0.00x | $-18.68 Million |
| 2019 | 0.00% | -9221.38% | 0.01x | 0.00x | $-22.58 Million |
| 2020 | 0.00% | -54140.26% | 0.00x | 0.00x | $-20.31 Million |
| 2021 | 0.00% | -36112.10% | 0.01x | 0.00x | $-28.83 Million |
| 2022 | 0.00% | -393667.27% | 0.00x | 0.00x | $-25.00 Million |
| 2023 | 0.00% | -275174.20% | 0.00x | 0.00x | $-24.12 Million |
Industry Comparison
This section compares Pharnext SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharnext SA (PNEXF) | $-33.95 Million | 0.00% | N/A | $413.33K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |